11th International ANRS HBV cure Workshop 2024
Program - July 3rd 2024
Lyon, France

8H45 - Welcome & Introduction – 5 min
Fabien Zoulim & Yazdan Yazdanpanah

Functional cure, clinical aspects – 55 min
Chairs: Vincent Leroy, Victor de Ledinghen
The new treatment guidelines for CHB and CHD: are we moving towards functional cure?
Markus Cornberg, Hannovre – 20 min
Impact of HBV DNA integration on functional cure
Patrick Kennedy, London – 20 min
Roundtable discussion – 15 min

9H45 Mechanisms of viral persistence – 1H15
Chairs: David Durantel, Hélène Strick-Marchand
Integrative analysis of HBV and immune cells in the liver compartment during antiviral therapy
Oliver Lenz, Janssen Belgium – 20 min
Novel insight in the regulation of cccDNA transcription
Barbara Testoni, Lyon – 20min
Mechanism of exhaustion of B and T cells and path for functional recovery
Robert Thimme, Freiburg – 20 min
Roundtable discussion – 15 min

11H00 - Coffee break – 20 min

11H20 Flash communications / young investigators – 1H30
Chairs: Christine Neuveut, Hugues de Rocquigny
6 talks/young investigators, 15 min each

12H50 - Lunch break – 1H10

14H00 HDV session – 1H20
Chairs: Julie Lucifora, Vincent Thibault
HDV origin in Homo Sapiens
Frederic Le Gal, Bobigny – 15 min
Insight on HDV – host cell interactions for drug discovery
Eloi Verrier, Strasbourg – 15 min
Mode of action of Nucleic Acid Polymers in HDV infection
Massimo Levrero, Lyon – 15 min
Intrahepatic decay of HDV during antiviral therapy
Pietro Lampertico, Milan – 15 min
Roundtable discussion – 20 min
15H20 - Coffee break – 20 min

15H40 Drug development 2H20
Chairs: Linda Wittkop, Fabien Zoulim

*Results of clinical trials of novel cure strategies*
Marc Bourlière, Marseille – 25 min (including 5 min discussion)

*CAM inhibitors as backbone treatments for functional cure*
Raymond Schinazi, Atlanta – 25 min (including 5 min discussion)

*Targeting HBV RNAs with novel ASOs*
Guofeng Cheng, AusperBio – 20 min (including 5 min discussion)

*Immunological correlates of functional cure*
Georg Lauer, Boston – 25 min (including 5 min discussion)

*DC-targeting vaccines for HIV and emerging infectious diseases: perspectives for HBV*
Yves Levy, Créteil – 25 min (including 5 min discussion)

Roundtable discussion: HBV & HDV cure challenges – 20 min

18H00 - Conclusions and Farewell – Fabien Zoulim